JP2025111616A5 - - Google Patents
Info
- Publication number
- JP2025111616A5 JP2025111616A5 JP2025071172A JP2025071172A JP2025111616A5 JP 2025111616 A5 JP2025111616 A5 JP 2025111616A5 JP 2025071172 A JP2025071172 A JP 2025071172A JP 2025071172 A JP2025071172 A JP 2025071172A JP 2025111616 A5 JP2025111616 A5 JP 2025111616A5
- Authority
- JP
- Japan
- Prior art keywords
- disorder
- disease
- compound
- pharmaceutically acceptable
- formula
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (6)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201910572272 | 2019-06-28 | ||
| CN201910572272.1 | 2019-06-28 | ||
| CN201911375262 | 2019-12-27 | ||
| CN201911375262.5 | 2019-12-27 | ||
| JP2021577929A JP7702887B2 (ja) | 2019-06-28 | 2020-06-28 | ニューロキニン－１アンタゴニスト |
| PCT/CN2020/098460 WO2020259675A1 (zh) | 2019-06-28 | 2020-06-28 | 神经激肽-1拮抗剂 |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021577929A Division JP7702887B2 (ja) | 2019-06-28 | 2020-06-28 | ニューロキニン－１アンタゴニスト |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2025111616A JP2025111616A (ja) | 2025-07-30 |
| JP2025111616A5 true JP2025111616A5 (enExample) | 2025-09-17 |
Family
ID=74059657
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021577929A Active JP7702887B2 (ja) | 2019-06-28 | 2020-06-28 | ニューロキニン－１アンタゴニスト |
| JP2025071172A Pending JP2025111616A (ja) | 2019-06-28 | 2025-04-23 | ニューロキニン－１アンタゴニスト |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021577929A Active JP7702887B2 (ja) | 2019-06-28 | 2020-06-28 | ニューロキニン－１アンタゴニスト |
Country Status (10)
| Country | Link |
|---|---|
| US (1) | US12421260B2 (enExample) |
| EP (1) | EP3991730A4 (enExample) |
| JP (2) | JP7702887B2 (enExample) |
| KR (1) | KR102940508B1 (enExample) |
| CN (2) | CN113905735B (enExample) |
| AU (1) | AU2020308397B2 (enExample) |
| BR (1) | BR112021026554A2 (enExample) |
| MX (1) | MX2021015827A (enExample) |
| TW (1) | TWI853965B (enExample) |
| WO (1) | WO2020259675A1 (enExample) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2024501994A (ja) * | 2020-12-25 | 2024-01-17 | 上海盛迪医▲葯▼有限公司 | Ｎｋ１拮抗剤プロドラッグ化合物と５－ｈｔ３受容体拮抗剤との併用使用 |
| CN114671913A (zh) * | 2020-12-25 | 2022-06-28 | 上海盛迪医药有限公司 | 一种神经激肽-1拮抗剂的晶型及其制备方法 |
| CA3247908A1 (en) * | 2022-01-12 | 2025-07-10 | Jiangsu Hengrui Pharmaceuticals Co., Ltd. | PHARMACEUTICAL COMPOSITION COMPRISING A NEUROKIN-1 ANTAGONIST PROMEDICINE COMPOUND |
| CA3247898A1 (en) | 2022-01-12 | 2025-07-10 | Jiangsu Hengrui Pharmaceuticals Co., Ltd. | CRYSTALLINE FORM OF A NEUROKIN-1 ANTAGONIST PRODIGITANT COMPOUND |
| CN119528985A (zh) | 2023-08-28 | 2025-02-28 | 科睿迪(南京)医药科技有限公司 | 神经激肽-1受体拮抗剂化合物 |
Family Cites Families (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP0666856B1 (en) | 1992-10-28 | 2000-01-05 | MERCK SHARP & DOHME LTD. | 4-arylmethyloxymethyl piperidines as tachykinin antagonists |
| JPH08504435A (ja) | 1992-12-14 | 1996-05-14 | メルク シヤープ エンド ドーム リミテツド | タキキニン受容体拮抗剤としての４−アミノメチル／チオメチル／スルホニルメチル−４−フェニルピペリジン |
| JPH09507500A (ja) | 1994-01-13 | 1997-07-29 | メルク シヤープ エンド ドーム リミテツド | ｇｅｍ二置換アザシクロ系のタキキニン拮抗薬 |
| WO1998022542A2 (en) * | 1996-11-08 | 1998-05-28 | Ikonos Corporation | Chemical functionalization of surfaces |
| PE20030762A1 (es) | 2001-12-18 | 2003-09-05 | Schering Corp | Compuestos heterociclicos como antagonistas nk1 |
| US7041682B2 (en) * | 2002-07-03 | 2006-05-09 | Schering Corporation | NK1 antagonists |
| KR20060113737A (ko) * | 2003-12-22 | 2006-11-02 | 쉐링 코포레이션 | 약제학적 조성물 |
| EP2464230B1 (en) * | 2009-08-14 | 2016-10-05 | OPKO Health, Inc. | Intravenous formulations of rolapitant |
| KR20180069934A (ko) | 2011-07-28 | 2018-06-25 | 켐팜 인코포레이티드 | 메틸페니데이트 프로드러그, 이의 제조 방법 및 사용 방법 |
| CN102775401B (zh) | 2012-08-15 | 2015-01-07 | 青岛农业大学 | 一种美洛昔康的合成方法 |
| CN108148060B (zh) * | 2016-12-05 | 2020-06-19 | 四川科伦博泰生物医药股份有限公司 | 取代的杂环化合物及其衍生物，其药物组合物、制备方法及用途 |
| CN107383008A (zh) * | 2017-08-14 | 2017-11-24 | 苏州信恩医药科技有限公司 | 一种罗拉匹坦的合成方法 |
-
2020
- 2020-06-28 KR KR1020227003091A patent/KR102940508B1/ko active Active
- 2020-06-28 CN CN202080040881.3A patent/CN113905735B/zh active Active
- 2020-06-28 WO PCT/CN2020/098460 patent/WO2020259675A1/zh not_active Ceased
- 2020-06-28 CN CN202410285183.XA patent/CN118324811A/zh active Pending
- 2020-06-28 AU AU2020308397A patent/AU2020308397B2/en active Active
- 2020-06-28 MX MX2021015827A patent/MX2021015827A/es unknown
- 2020-06-28 BR BR112021026554A patent/BR112021026554A2/pt unknown
- 2020-06-28 JP JP2021577929A patent/JP7702887B2/ja active Active
- 2020-06-28 EP EP20831251.2A patent/EP3991730A4/en active Pending
- 2020-06-28 US US17/623,205 patent/US12421260B2/en active Active
- 2020-06-29 TW TW109121881A patent/TWI853965B/zh active
-
2025
- 2025-04-23 JP JP2025071172A patent/JP2025111616A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN1227251C (zh) | 由芳基烷基胺得到的氨基甲酸酯 | |
| CN1122018C (zh) | 作为药用活性成分的6－二甲氨基甲基－1－苯基环己烷化合物 | |
| JP3819933B2 (ja) | 血管収縮性ジヒドロベンゾピラン誘導体 | |
| DE69906389T2 (de) | Verfahren zur herstellung von citalopram | |
| JP2011517443A5 (enExample) | ||
| JP2021513975A5 (enExample) | ||
| JP2004516278A (ja) | 一酸化窒素合成酵素阻害物質であるリン酸塩 | |
| JP2015504053A (ja) | 脳卒中の治療または予防に使用されるするためのフェニルカルバメート化合物 | |
| PT1028940E (pt) | Processo para produzir oxazolidinonas | |
| CN1383423A (zh) | 6－氟双环[3.1.0]己烷衍生物 | |
| JP2015063529A (ja) | アルホルモテロールの合成方法 | |
| US8563547B2 (en) | (6,7-dihydro-2-nitro-5H-imidazol[2,1-b][1,3]oxazin-6-yl) amide compounds, preparation methods and uses thereof | |
| WO2004113352A1 (en) | Silylated heterocyclylurea derivatives as cytokine-inhibitors | |
| JP2020510041A5 (enExample) | ||
| JP2025506504A5 (enExample) | ||
| JP5774694B2 (ja) | フェニルカルバメート化合物およびこれを含む筋肉弛緩剤 | |
| JP2019537624A5 (enExample) | ||
| US20220064111A1 (en) | Enantioselective synthesis of brivaracetam and intermediates thereof | |
| JP2008509896A (ja) | 保護化アミノチアゾールのフッ素化方法 | |
| JPH10504820A (ja) | Ｎ−置換されたフェノチアジン類の使用 | |
| JP2023511152A5 (enExample) | ||
| JP4866352B2 (ja) | ２−オキソ−１−ピロリジン誘導体の製造方法 | |
| JP2020507567A5 (enExample) | ||
| KR20100074303A (ko) | Ｏ-데스메틸벤라팍신 푸마레이트의 결정형 | |
| TWI876414B (zh) | R-mdma的製造方法 |